Coulter Partners places seasoned biopharmaceutical industry executives to Altimmune Board of Directors

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications.

Commenting on the search work with Coulter Partners, Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune, said:

“Coulter Partners’ deep life sciences expertise and proactive approach helped us secure top-tier talent. We value our partnership and look forward to continuing our collaboration.”